Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:DYN NASDAQ:KOD NASDAQ:MESO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$13.09+1.4%$11.99$3.98▼$13.68$1.99B1.932.01 million shs457,021 shsDYNDyne Therapeutics$13.38+3.0%$11.39$6.36▼$37.08$1.90B1.12.59 million shs697,685 shsKODKodiak Sciences$9.44+1.2%$8.10$1.92▼$11.60$498.57M2.45447,494 shs75,174 shsMESOMesoblast$15.25-2.2%$14.68$6.09▼$22.00$1.95B2.26272,130 shs63,874 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.30%+2.38%-1.00%+23.30%+181.26%DYNDyne Therapeutics+1.01%-1.96%+4.93%+20.50%-62.24%KODKodiak Sciences-0.21%-7.26%-11.73%+164.31%+248.13%MESOMesoblast+0.91%+4.00%-4.00%+33.45%+153.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$13.09+1.4%$11.99$3.98▼$13.68$1.99B1.932.01 million shs457,021 shsDYNDyne Therapeutics$13.38+3.0%$11.39$6.36▼$37.08$1.90B1.12.59 million shs697,685 shsKODKodiak Sciences$9.44+1.2%$8.10$1.92▼$11.60$498.57M2.45447,494 shs75,174 shsMESOMesoblast$15.25-2.2%$14.68$6.09▼$22.00$1.95B2.26272,130 shs63,874 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.30%+2.38%-1.00%+23.30%+181.26%DYNDyne Therapeutics+1.01%-1.96%+4.93%+20.50%-62.24%KODKodiak Sciences-0.21%-7.26%-11.73%+164.31%+248.13%MESOMesoblast+0.91%+4.00%-4.00%+33.45%+153.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.88Moderate Buy$12.38-5.49% DownsideDYNDyne Therapeutics 3.06Buy$34.07154.70% UpsideKODKodiak Sciences 2.00Hold$11.7524.47% UpsideMESOMesoblast 3.20Buy$18.0018.03% UpsideCurrent Analyst Ratings BreakdownLatest KOD, ADPT, MESO, and DYN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$31.00 ➝ $35.008/18/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$3.00 ➝ $5.008/14/2025KODKodiak SciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$4.00 ➝ $7.008/14/2025KODKodiak SciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$15.008/6/2025ADPTAdaptive BiotechnologiesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $14.008/6/2025ADPTAdaptive BiotechnologiesTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $15.008/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$13.00 ➝ $15.008/6/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$34.00 ➝ $13.008/5/2025MESOMesoblastCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/31/2025DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$66.00 ➝ $36.007/29/2025DYNDyne TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $23.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M11.14N/AN/A$1.37 per share9.56DYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/AKODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/AMESOMesoblast$17.20M113.49N/AN/A$4.67 per share3.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.82N/AN/AN/A-59.07%-60.93%-23.03%11/6/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.80N/AN/AN/AN/A-155.27%-63.29%11/13/2025 (Estimated)MESOMesoblast-$102.14MN/A0.00N/AN/AN/AN/AN/AN/ALatest KOD, ADPT, MESO, and DYN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025KODKodiak Sciences-$1.01-$1.03-$0.02-$1.03N/AN/A8/5/2025Q2 2025ADPTAdaptive Biotechnologies-$0.24-$0.17+$0.07-$0.17$49.40 million$49.94 million7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.842.75DYNDyne Therapeutics0.1716.8316.83KODKodiak SciencesN/A3.483.48MESOMesoblast0.111.991.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%DYNDyne Therapeutics96.68%KODKodiak Sciences89.06%MESOMesoblast1.43%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%DYNDyne Therapeutics20.77%KODKodiak Sciences45.90%MESOMesoblast18.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790152.27 million142.53 millionOptionableDYNDyne Therapeutics100142.26 million112.72 millionOptionableKODKodiak Sciences9052.82 million28.58 millionOptionableMESOMesoblast80128.00 million103.93 millionOptionableKOD, ADPT, MESO, and DYN HeadlinesRecent News About These CompaniesMesoblast (NASDAQ:MESO) Shares Gap Up - Still a Buy?September 16 at 2:17 PM | marketbeat.comSuccessful Commercial Launch of Ryoncil® Highlighted at Global Healthcare ConferencesSeptember 14 at 9:18 PM | globenewswire.comMesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?September 14 at 11:27 AM | marketbeat.comMesoblast Limited $MESO Shares Acquired by Cubist Systematic Strategies LLCSeptember 12, 2025 | marketbeat.comMesoblast shares lift following $76m convertible note agreementsSeptember 5, 2025 | msn.comHotCopper Trends: Mesoblast raising $50M; Larvotto hits & Alterity HaltSeptember 4, 2025 | msn.comMesoblast Secures Option for $50 Million Convertible Notes to Bolster GrowthSeptember 4, 2025 | msn.comMesoblast Enters Into Option To Issue US$50 Million Convertible NotesSeptember 3, 2025 | globenewswire.comMesoblast Limited (NASDAQ:MESO) Given Consensus Rating of "Buy" by BrokeragesSeptember 3, 2025 | marketbeat.comMesoblast Limited (NASDAQ:MESO) Q4 2025 Earnings Call TranscriptSeptember 2, 2025 | insidermonkey.comMesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?August 31, 2025 | marketbeat.comMesoblast Full Year 2025 Earnings: Misses ExpectationsAugust 29, 2025 | finance.yahoo.comMesoblast Limited 2025 Q4 - Results - Earnings Call PresentationAugust 29, 2025 | seekingalpha.comBanner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®August 28, 2025 | globenewswire.comExamining the Future: Mesoblast's Earnings OutlookAugust 27, 2025 | benzinga.comExamining the Future: Mesoblast's Earnings OutlookAugust 27, 2025 | benzinga.comMesoblast (MESO) to Release Quarterly Earnings on WednesdayAugust 21, 2025 | marketbeat.comMESO | Mesoblast Ltd. ADR Annual Income Statement | MarketWatchAugust 14, 2025 | marketwatch.comUlcerative Colitis Treatment Landscape Undergoes Rapid Transformation with FDA Approvals and Robust Pipeline | DelveInsightAugust 13, 2025 | theglobeandmail.comJPMorgan Acquires Substantial Stake in MesoblastJuly 23, 2025 | msn.comMesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should KnowJuly 22, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, ADPT, MESO, and DYN Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$13.09 +0.18 (+1.43%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Dyne Therapeutics NASDAQ:DYN$13.38 +0.39 (+2.96%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Kodiak Sciences NASDAQ:KOD$9.44 +0.11 (+1.18%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Mesoblast NASDAQ:MESO$15.25 -0.35 (-2.24%) As of 12:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
